The effects of extracorporeal cardiopulmonary circulation on serum total and free prostate specific antigen levels
-
Yılmaz Aksoy
Abstract
The aim of this study was to investigate whether or not there is an increase in serum total and free prostate specific antigen levels (t-PSA, f-PSA) in patients with and without benign prostatic hyperplasia (BPH) undergoing extracorporeal circulation during cardiovascular bypass. The study included a total of 50 men. Of these, 35 patients underwent elective coronary artery bypass grafting with extracorporeal circulation [with (n=20, group I) and without (n=15, group II) BPH]. Another 15 patients underwent renal or ureteral surgery (group III) and served as a control group. Serum t-PSA and f-PSA levels were measured before surgery and 3h and 3days after surgery. All patients underwent urethral catheterization 24h before surgery. In groups I and II, patients had an increase in t-PSA 3h after surgery compared to baseline values (p=0.0001 and p=0.011, respectively). Also, 3days after surgery, mean t-PSA levels were higher than baseline levels (p=0.004) in group I. Serum t-PSA levels were higher at 3h than at day 3 in groups I and II (p=0.003 and p=0.02, respectively). Mean serum f-PSA levels obtained 3h after surgery were increased in both groups I and II when compared to baseline values (p=0.0001 and p=0.001, respectively). There was no significant difference between f-PSA values before and 3days after surgery in all groups. In the control group, there was no significant increase in either serum t-PSA or f-PSA levels obtained at different times. There was a modest increase in the percentage of free prostate specific antigen (% f-PSA) 3h after the operation in group II (p=0.025); the values returned to baseline within 3days. It was suggested that t-PSA and f-PSA serum levels increase due to extracorporeal cardiopulmonary circulation as a consequence of ischemic damage to the prostate. In patients with BPH, this rise may be higher than in those without BPH, because BPH patients generally have larger prostate volumes that may be more vulnerable to ischemic damage. Because f-PSA has a shorter half-life, postsurgical levels of f-PSA may not show this ischemic damage to the prostate during the late postoperative period and f-PSA appears to be cleared more rapidly than t-PSA.
References
1 Schellhammer PL, Wright GL Jr. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin N Am 1993; 20: 597–606. 10.1016/S0094-0143(21)00913-7Search in Google Scholar
2 McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995; 54: 729–44. 10.1016/S0090-4295(99)80076-4Search in Google Scholar
3 Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001; 57: 1105–11. 10.1016/S0090-4295(01)00953-0Search in Google Scholar
4 Lechevallier E, Eghazarian C, Ortega JC, Roux F, Coulange C. Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen. Urology 1999; 54: 857–61. 10.1016/S0090-4295(99)00239-3Search in Google Scholar
5 Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407–13. 10.1016/S0022-5347(01)67064-2Search in Google Scholar
6 Ornstein DK, Rao GS, Smith DS, Ratliff TL, Basler JW, Catalona WJ. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol 1997; 157: 195–8. 10.1016/S0022-5347(01)65321-7Search in Google Scholar
7 Hagood PG, Parra RO, Rauscher JA. Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass. J Urol 1994; 152: 2043–5. 10.1016/S0022-5347(17)32301-7Search in Google Scholar
8 Coker C, Sherwood RA, Crayford T, Saadeh F, Mulvin D, Brakenbury E, et al. Ischemic damage to the prostate during cardiac surgery: a clinical model. Prostate 1997; 32: 85–8. 10.1002/(SICI)1097-0045(19970701)32:2<85::AID-PROS2>3.0.CO;2-ESearch in Google Scholar
9 Netto NR, Lima ML, Guedes MA, Patino LL, de Oliveira JB. Elevation of prostate specific antigen in cardiac surgery with extracorporeal cardiopulmonary circulation. J Urol 1998; 159: 875–7. 10.1016/S0022-5347(01)63759-5Search in Google Scholar
10 Lechevallier E, Echazarian C, Ortega JC, Daniel L, Roux F, Thirion X, et al. Kinetics of postbiopsy levels of serum free prostate-specific antigen and percent free prostate-specific antigen. Urology 1999; 53: 731–5. 10.1016/S0090-4295(98)00607-4Search in Google Scholar
11 Rodriguez-Rubio FI, Robles JE, Gonzalez A, Arocena J, Sanz G, Diez-Caballero F, et al. Effect of digital rectal examination and flexible cystoscopy on free and total prostate-specific antigen, and the percentage of free prostate-specific antigen. Differences between two PSA assays. Eur Urol 1998; 33: 255–60. Search in Google Scholar
12 Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618–25. 10.1093/clinchem/37.9.1618Search in Google Scholar
13 Partin AW, Piantadosi S, Subong EN, Kelly CA, Hortopan S, Chan DW, et al. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate Suppl 1996; 7: 35–9. 10.1002/(SICI)1097-0045(1996)7+<35::AID-PROS5>3.0.CO;2-ISearch in Google Scholar
14 Oberpenning F, Schmid HP, Fuchs-Surdel W, Hertle L, Semjonow A. The impact of intraoperative manipulation of the prostate on total and free prostate-specific antigen. Int J Biol Markers 2002; 17: 154–60. 10.1177/172460080201700302Search in Google Scholar
15 Bjork T, Ljungberg B, Piironen T, Abrahamsson PA, Pettersson K, Cockett AT, et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology 1998; 51: 57–62. 10.1016/S0090-4295(97)00572-4Search in Google Scholar
16 Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991; 30: 1723–30. 10.1021/bi00220a039Search in Google Scholar
17 Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 187–94. 10.1016/S0090-4295(99)80192-7Search in Google Scholar
18 Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J Am Med Assoc 1995; 274: 1214–20. 10.1001/jama.1995.03530150038031Search in Google Scholar
19 Benson MC. Prostate specific antigen. J Urol 1994; 152: 2046–8. 10.1016/S0022-5347(17)32302-9Search in Google Scholar
20 Benson MC, Olsson CA. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. Cancer 1994; 74: 1667–73. Search in Google Scholar
©2005 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Pathophysiology and diagnostic value of urinary trypsin inhibitors
- Apolipoprotein H (apoH)-dependent autoantibodies and apoH protein polymorphism in selected patients showing lupus anticoagulant activity
- Differential production of immunoglobulin classes and subclasses by mucosal-type human B-lymphocytes exposed in vitro to CpG oligodeoxynucleotides
- The predictive power of serum κ/λ ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma
- The soluble transferrin receptor (sTfR)-ferritin index is a potential predictor of celiac disease in children with refractory iron deficiency anemia
- Monitoring of fibrinolysis parameters during myocardial revascularization according to type of procedure
- Serum amyloid A protein levels as a possible aid in the diagnosis of acute appendicitis in children
- External failures as descriptor of quality in clinical microbiology laboratory services
- The effects of extracorporeal cardiopulmonary circulation on serum total and free prostate specific antigen levels
- Quantitative automated human chorionic gonadotropin measurement in urine using the Modular Analytics E170 module (Roche)
- Interference of dextran in biuret-type assays of serum proteins
- Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport
- Evaluation of a new automated electrochemiluminescent sex hormone-binding globulin (SHBG) immunoassay
- The late Greco-Roman and Byzantine contribution towards the evolution of laboratory examinations of bodily excrement. Part 2: sputum, vomit, blood, sweat, autopsies
- Faecal elastase 1 measurement in chronic pancreatitis
- On the origin of BÄK requirements for imprecision
- Reference intervals for serum thyrotropin (TSH) and free thyroxine (FT4) in adults using the Access ® Immunoassay System
- Erythrocyte glutathione and serum total glutathione-S-transferase in epilepsy
- CCLM - Guidelines for Authors
Articles in the same Issue
- Pathophysiology and diagnostic value of urinary trypsin inhibitors
- Apolipoprotein H (apoH)-dependent autoantibodies and apoH protein polymorphism in selected patients showing lupus anticoagulant activity
- Differential production of immunoglobulin classes and subclasses by mucosal-type human B-lymphocytes exposed in vitro to CpG oligodeoxynucleotides
- The predictive power of serum κ/λ ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma
- The soluble transferrin receptor (sTfR)-ferritin index is a potential predictor of celiac disease in children with refractory iron deficiency anemia
- Monitoring of fibrinolysis parameters during myocardial revascularization according to type of procedure
- Serum amyloid A protein levels as a possible aid in the diagnosis of acute appendicitis in children
- External failures as descriptor of quality in clinical microbiology laboratory services
- The effects of extracorporeal cardiopulmonary circulation on serum total and free prostate specific antigen levels
- Quantitative automated human chorionic gonadotropin measurement in urine using the Modular Analytics E170 module (Roche)
- Interference of dextran in biuret-type assays of serum proteins
- Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport
- Evaluation of a new automated electrochemiluminescent sex hormone-binding globulin (SHBG) immunoassay
- The late Greco-Roman and Byzantine contribution towards the evolution of laboratory examinations of bodily excrement. Part 2: sputum, vomit, blood, sweat, autopsies
- Faecal elastase 1 measurement in chronic pancreatitis
- On the origin of BÄK requirements for imprecision
- Reference intervals for serum thyrotropin (TSH) and free thyroxine (FT4) in adults using the Access ® Immunoassay System
- Erythrocyte glutathione and serum total glutathione-S-transferase in epilepsy
- CCLM - Guidelines for Authors
